A wholly-owned subsidiary of Jaguar Health Inc (NASDAQ:JAGX), Napo Pharmaceuticals, on August 23, 2021, announced an abstract related to an exploratory clinical study. It delves into the impact of crofelemer on the gastrointestinal microbiome in people suffering from AIDS and has been given for presentation consideration at IDWeek 2021, taking place virtually from September 29 to October 3.
Mytesi (crofelemer), an antidiarrheal drug for the relief of noninfectiousdiarrhea in adults with HIV ensures changes in gut microbiota and may result in HIV-1 related gut inflammation.
The study assesses the impact of crofelemer on the microbiota of HIV-negative and PLWHA subjects after a month of oral dosing, for testing crofelemer’s physiological mechanism of action in the gut lumen.
Joint annual meeting of Infectious Diseases Society of America, IDWeek will have Society for Healthcare Epidemiology of America, HIV Medical Association, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Users can get more information on the event on its site: https://idweek.org.
Mytesi is not indicated for the treatment of infectious diarrhea.
Jaguar Health, a commercial stage pharmaceuticals company, focuses on developing unique, plant-based as well and sustainably derived prescription medicines for animals and people having GI distress, specifically chronic and weakening diarrhea.
